The Fc-engineered CD19 antibody MOR208 (XmAb5574) induces natural killer cell-mediated lysis of acute lymphoblastic leukemia cells from pediatric and adult patients

Leukemia

Volumn 27, Issue 7, 2013, Pages 1595-1598

  Kellner, C ^a   Zhukovsky, E A ^b,d   Potzke A ^a   Bruggemann M ^c   Schrauder, A ^c   Schrappe, M ^c   Kneba, M ^c   Repp, R ^a   Humpe, A ^a   Gramatzki, M ^a   Peipp, M ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b Xencor Inc   (United States)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d Affimed GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; CD19 ANTIBODY; CD19 ANTIBODY MOR 208; IMMUNOGLOBULIN G; RITUXIMAB; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG; XMAB 5574;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY ENGINEERING; CANCER INHIBITION; CELL POPULATION; CHIMERA; CHRONIC LYMPHATIC LEUKEMIA; COMPETITIVE INHIBITION; CONSOLIDATION CHEMOTHERAPY; CORRELATION ANALYSIS; CYTOLYSIS; EFFECTOR CELL; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL; HUMAN; IN VITRO STUDY; LETTER; LEUKEMIA CELL LINE; MACROPHAGE; MINIMAL RESIDUAL DISEASE; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; WILD TYPE;

ANTIBODIES; ANTIGENS, CD19; FEMALE; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; KILLER CELLS, NATURAL; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRIMARY CELL CULTURE;

EID: 84880296871     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.373     Document Type: Letter

References (15)

1. Hoelzer D, Gökbuget N. Chemoimmunotherapy in acute lymphoblastic leukemia. Blood Rev 2012; 26: 25-32.
2. Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman SF, Nadler LM. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 1984; 63: 1424-1433.
3. Kellner C, Bruenke J, Stieglmaier J, Schwemmlein M, Schwenkert M, Singer H et al. A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells. J Immunother 2008; 31: 871-884.
4. Lang P, Barbin K, Feuchtinger T, Greil J, Peipp M, Zunino SJ et al. Chimeric CD19 antibody mediates cytotoxic activity against leukemic blasts with effector cells from pediatric patients who received T-cell-depleted allografts. Blood 2004; 103: 3982-3985.
5. Ward E, Mittereder N, Kuta E, Sims GP, Bowen MA, Dall'Acqua W et al. A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo. Br J Haematol 2011; 155: 426-437.
6. Cochlovius B, Kipriyanov SM, Stassar MJ, Schuhmacher J, Benner A, Moldenhauer G et al. Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3 x CD19 tandem diabody, and CD28 costimulation. Cancer Res 2000; 60: 4336-4341.
7. Horton HM, Bernett MJ, Pong E, Peipp M, Karki S, Chu SY et al. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res 2008; 68: 8049-8057.
8. Topp MS, Kufer P, Gökbuget N, Goebeler M, Klinger M, Neumann S et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapyrefractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011; 29: 2493-2498.
9. Nimmerjahn F, Ravetch JV. Antibodies, Fc receptors and cancer. Curr Opin Immunol 2007; 19: 239-245.
10. de Haij S, Jansen JH, Boross P, Beurskens FJ, Bakema JE, Bos DL et al. In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling. Cancer Res 2010; 70: 3209-3217.
11. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21: 3940-3947.
12. Desjarlais JR, Lazar GA, Zhukovsky EA, Chu SY. Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective. Drug Discov Today 2007; 12: 898-910.
13. Zalevsky J, Leung IW, Karki S, Chu SY, Zhukovsky EA, Desjarlais JR et al. The impact of Fc engineering on an anti-CD19 antibody: increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman primates. Blood 2009; 113: 3735-3743.
14. Awan FT, Lapalombella R, Trotta R, Butchar JP, Yu B, Benson Jr. DM et al. CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody. Blood 2010; 115: 1204-1213.
15. Rafiq S, Cheney C, Mo X, Jarjoura D, Muthusamy N, Byrd JC. XmAb-5574 antibody demonstrates superior antibody-dependent cellular cytotoxicity as compared with CD52- and CD20-targeted antibodies in adult acute lymphoblastic leukemia cells. Leukemia 2012; 26: 1720-1722.